Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Jacqueline Vuky; Richard Yu; Lawrence Schwartz; Robert J. Motzer

doi:10.1023/A:1016270206374

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Jacqueline Vuky, Richard Yu, Lawrence Schwartz, Robert J. Motzer

Research output: Contribution to journal › Article › peer-review

75 Scopus citations

Abstract

Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As₂O₃). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

Original language	English (US)
Pages (from-to)	327-330
Number of pages	4
Journal	Investigational New Drugs
Volume	20
Issue number	3
DOIs	https://doi.org/10.1023/A:1016270206374
State	Published - 2002
Externally published	Yes

Keywords

Arsenic trioxide
Metastatic renal cell carcinoma
Phase II trial

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1023/A:1016270206374

Cite this

@article{e0de0a98b37646289e55b31f2aa3a42c,

title = "Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma",

abstract = "Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.",

keywords = "Arsenic trioxide, Metastatic renal cell carcinoma, Phase II trial",

author = "Jacqueline Vuky and Richard Yu and Lawrence Schwartz and Motzer, {Robert J.}",

note = "Funding Information: Supported in part by NIH Grants K24 CA-82431, CA-0582, 5T32-CA-09207-23 (Cancer Chemotherapy Training Program), and the Brian Piccolo Cancer Research Fund.",

year = "2002",

doi = "10.1023/A:1016270206374",

language = "English (US)",

volume = "20",

pages = "327--330",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "3",

}

TY - JOUR

T1 - Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

AU - Vuky, Jacqueline

AU - Yu, Richard

AU - Schwartz, Lawrence

AU - Motzer, Robert J.

N1 - Funding Information: Supported in part by NIH Grants K24 CA-82431, CA-0582, 5T32-CA-09207-23 (Cancer Chemotherapy Training Program), and the Brian Piccolo Cancer Research Fund.

PY - 2002

Y1 - 2002

N2 - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

AB - Fourteen patients with metastatic renal cell carcinoma (RCC) were treated on a Phase II trial with arsenic trioxide (As2O3). Eligible patients had metastatic renal cell carcinoma with bidimensionally measurable disease, a Karnofsky performance status of at least 70%, life expectancy of greater than three months, and no evidence of brain metastases. Arsenic trioxide was given intravenously at a dose of 0.3 mg/kg/day for five consecutive days every four weeks. The most common toxicity observed was grade II elevation in liver function tests (36%), anemia (21%), renal insufficiency (14%), rash (7%), and diarrhea (7%). Best response was stable disease in 3 patients with one patient remaining on study at 8+ months At the dose and schedule used in this trial, arsenic trioxide did not achieve a complete or partial response in metastatic renal cell carcinoma.

KW - Arsenic trioxide

KW - Metastatic renal cell carcinoma

KW - Phase II trial

UR - http://www.scopus.com/inward/record.url?scp=0036021225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036021225&partnerID=8YFLogxK

U2 - 10.1023/A:1016270206374

DO - 10.1023/A:1016270206374

M3 - Article

C2 - 12201495

AN - SCOPUS:0036021225

SN - 0167-6997

VL - 20

SP - 327

EP - 330

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 3

ER -

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this